OBJECTIVE To describe Canadian family physicians ’ prescribing practices with regard to Alzheimer disease (AD). DESIGN Cross-sectional survey administered by facsimile. SETTING Four regions in Canada (British Columbia, the Prairie Provinces, Ontario, and the Atlantic Provinces). PARTICIPANTS A stratifi ed random sample of 1000 Canadian family physicians (250 per region) chosen from the Canadian Medical Directory; 81 of whom were excluded as ineligible. MAIN OUTCOME MEASURES Prescribing practices regarding cholinesterase inhibitors (ChIs) for patients with AD. RESULTS Response rate was 36.3%. About 27 % of respondents reported that ChIs were prescribed for less than 10% of their AD patients, while 12.5 % reported that ChIs were prescribed fo...
Introduction: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60–80% of ...
Background: The Australian Pharmaceutical Benefits Scheme (PBS) first subsidized cholinesteraseinhib...
Care plans are intended to improve the independence and functioning of patients with cognitive dysfu...
Thesis (Master's)--University of Washington, 2021Background: The U.S. healthcare workforce is insuff...
OBJECTIVE To review the evidence regarding prevention of Alzheimer disease (AD) in order to highligh...
Introduction. Research into medications for Alzheimer's disease (AD) is primarily conducted in drug...
Introduction: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60–80% of ...
Alzheimer’s disease (AD) is the most common form of dementia accounting for 60–80% of dementia diagn...
Background: In the UK, the National Institute for Health and Clinical Excellence (NICE) is currently...
Purpose: This study was designed to examine the prevalence of cholinesterase inhibitor (ChEI) use an...
Alzheimer’s Disease (AD) is the most prevalent type of dementia and has a high prevalence in the agi...
Background: Systematic evidence became available in the late 1990s on efficacy of cholinesterase inh...
Aim: Thorough diagnostics are a prerequisite for the optimal treatment of Alzheimer’s disease (AD). ...
cholinesterase inhibitors (done-pezil, galantamine and rivastig-mine) have been shown to have benefi...
The diagnostic process for patients presenting with cognitive decline and suspected dementia is comp...
Introduction: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60–80% of ...
Background: The Australian Pharmaceutical Benefits Scheme (PBS) first subsidized cholinesteraseinhib...
Care plans are intended to improve the independence and functioning of patients with cognitive dysfu...
Thesis (Master's)--University of Washington, 2021Background: The U.S. healthcare workforce is insuff...
OBJECTIVE To review the evidence regarding prevention of Alzheimer disease (AD) in order to highligh...
Introduction. Research into medications for Alzheimer's disease (AD) is primarily conducted in drug...
Introduction: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60–80% of ...
Alzheimer’s disease (AD) is the most common form of dementia accounting for 60–80% of dementia diagn...
Background: In the UK, the National Institute for Health and Clinical Excellence (NICE) is currently...
Purpose: This study was designed to examine the prevalence of cholinesterase inhibitor (ChEI) use an...
Alzheimer’s Disease (AD) is the most prevalent type of dementia and has a high prevalence in the agi...
Background: Systematic evidence became available in the late 1990s on efficacy of cholinesterase inh...
Aim: Thorough diagnostics are a prerequisite for the optimal treatment of Alzheimer’s disease (AD). ...
cholinesterase inhibitors (done-pezil, galantamine and rivastig-mine) have been shown to have benefi...
The diagnostic process for patients presenting with cognitive decline and suspected dementia is comp...
Introduction: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60–80% of ...
Background: The Australian Pharmaceutical Benefits Scheme (PBS) first subsidized cholinesteraseinhib...
Care plans are intended to improve the independence and functioning of patients with cognitive dysfu...